DMK Pharmaceuticals Expects Nasdaq Delisting Amid Bankruptcy

DMK Pharmaceuticals (DMK) has released an update to notify the public and investors about a regulation fd disclosure.

Facing Chapter 11 bankruptcy, a company anticipates a delisting notice from Nasdaq after failing to meet the necessary eligibility requirements. This expected delisting is a direct consequence of the company’s financial troubles and will not alter its obligation to report to the SEC, despite the anticipated removal of its common stock from the exchange.

For further insights into DMK stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.